The key benchmark was meaningful enough efficacy to advance RA monotherapy, and the filing says that bar was not cleared. The result was not a clean failure: low-dose SPY072 statistically improved the primary DAS28-CRP endpoint, while other dose-endpoint combinations showed nominal significance. But Spyre explicitly says the magnitude did not justify prioritizing the program in RA.
The efficacy signal is narrower than the headline suggests. Both doses are described as statistically significant on one or more endpoints, but the primary result came from low dose, the ACR20 signal from high dose was only nominally significant, and ACR50 significance was reported for low dose. The release provides no effect sizes, response rates, confidence intervals, or p-values, so the depth and clinical importance of the benefit cannot be independently judged from this filing. 〔0〕
| Measure | SPY072 | Placebo |
|---|---|---|
| Adverse events | 27% | 36% |
| Infections and infestations | 14% | 15% |
| Serious TEAEs | 1 | 1 |
| Deaths | 0 reported | 1 |
Safety was reassuring, but it does not offset the efficacy shortfall. Adverse-event rates were numerically lower with SPY072 than placebo, infections were nearly identical, and neither serious treatment-emergent event was considered drug-related.
The read-through shifts SPY072 away from RA monotherapy and toward combinations or other diseases. Spyre is preserving the broader TL1A strategy, including SPY072 in psoriatic arthritis and axial spondyloarthritis, plus an IL-17A/F combination in hidradenitis suppurativa. Those upcoming studies were already scheduled rather than created by this release; the next named catalyst is the September 2026 SKYLINE Part A readout. The RA result itself was a scheduled Q3 event, not a timing surprise.
Read the original 8-K on SEC EDGAR ↗